

Regioselective Transformation of Malic Acid: A Practical Method for the Construction of Enantiomerically Pure Indolizidines



Peter Gmeiner*[†] and Dagmar Junge[‡]

Pharmazeutisches Institut der Universität Bonn,
An der Immenburg 4, D-53121 Bonn, Germany, and
Institut für Pharmazie und Lebensmittelchemie der
Universität München, Sophienstrasse 10,
D-80333 München, Germany

Received January 24, 1995

Selective transformation of readily available chiral building blocks has become a major method for the synthesis of enantiomerically pure bioactive compounds including a large number of natural products.¹ In our previous publications,^{2,3} we have presented the synthesis of enantiomerically pure 1,2- as well as 1,3-amino alcohols employing L-aspartic acid as an educt. The key strategy was a regioselective functionalization of the (dibenzylamino)butanediol **1** (Scheme 1). Application of this methodology gave access to 8a-epi- and 1,8a-diepi-slaframines **3a,b**, both containing an equatorial amino group in position 6.³ The *trans*-configuration between positions 6 and 8a is due to a thermodynamically induced epimerization at the stage of the intermediate **2**. In contrast, natural slaframine (**6**), a strong muscarinic agonist,⁴ is characterized by an axial-orientated amino substituent.⁵

As an extension of these studies, we envisioned regioselective functionalization of the (benzyloxy)butanediol **4**,⁶ which should be readily available from (*R*)-malic acid. Employing the protocol we have presented for **3a,b**, we expected this strategy to give access to the 6,8a-*trans*-configured (1*S*,6*R*,8*S*)-dihydroxyindolizidine moiety as



a partial structure of the glycosidase inhibitor castanospermine.⁷ Furthermore, a suitable didesoxycastanospermine derivative (**5**) was planned to give access to natural slaframine (**6**), when stereospecific S_N2 displacement at position 6 was expected to induce 6,8a-*cis* stereochemistry.

For the synthesis of a selectively protected butane-1,2,4-triol, (*R*)-methyl malate (**7**) was reacted with benzyl bromide, resulting in formation of the benzyl ether **8** (Scheme 2).⁸ Subsequent reduction by LiAlH₄ gave the (benzyloxy)butanediol **4**. Due to a remote protecting group effect of the *N,N*-dibenzylamine substituent, we have recently observed regioselective silylation of the diol **1** by TBDMS-Cl or TBDPS-Cl.³ Analogous regiodifferentiation of a benzyloxy substituent was expected to induce a preferred silylation of **4** in position 4. Actually, imidazole-assisted reaction of **4** with TBDMS-Cl or TBDPS-Cl resulted in formation of the regioisomers **9a,b** and **10a,b** as well as the bis-silylation products **11a,b** in a 3:2:3 and a 5:1:3.5 ratio, respectively. TBDPS-Cl was the more selective reagent. However, complete separation of the isomers proved to be difficult. In contrast, an improved regioselectivity and easy purification of the major isomer by flash chromatography was observed

(7) For review, see: Michael, J. P. *Nat. Prod. Rep.* **1993**, 51.

(8) For previous syntheses of the (*S*)-enantiomer, see: (a) Barton, D. H. R.; Benechie, M.; Khuong-Huu, F.; Potier, P.; Reyna-Pinedo V. *Tetrahedron Lett.* **1982**, 23, 651. Keck, G. E.; Andrus, M. B.; Romer, D. R. *J. Org. Chem.* **1991**, 56, 417.

(9) For review, see: Greene, T. W.; Wuts, P. G. M. *Protective Groups in Organic Synthesis*, 2nd ed.; Wiley: New York, 1991.

[†] Pharmazeutisches Institut der Universität Bonn.

[‡] Institut für Pharmazie und Lebensmittelchemie der Universität München.

(1) Coppola, G. M.; Schuster, H. F. *Asymmetric Synthesis*; Wiley, New York, 1987.

(2) (a) Gmeiner, P.; Kärtner, A.; Junge, D. *Tetrahedron Lett.* **1993**, 34, 4325. (b) Gmeiner, P.; Kärtner, A. *Synthesis* **1995**, 83.


(3) Gmeiner, P.; Junge, D.; Kärtner, A. *J. Org. Chem.* **1994**, 59, 6766.

(4) For biological effects of slaframine, see: (a) Rainey, D. P.; Smalley, E. B.; Crumpp, M. P.; Strong, F. M. *Nature (London)* **1965**, 205, 203. (b) Aust, S. D.; Broquist, H. P. *Nature (London)* **1965**, 205, 204. (c) Guengenich, F. P.; Aust, S. D. *Mol. Pharmacol.* **1977**, 13, 185. (d) Guengenich, F. P.; Broquist, H. P. In *Bioorganic Chemistry*; van Tamelen, E. E., Ed.; Academic Press: New York, 1979; Vol. 2, pp 97-109. (e) Elbein, A. D.; Molyneux, R. J. In *Alcaloids: Chemical and Biological Perspectives*; Pelletier, S. W., Ed.; Wiley: New York, 1987; Vol. 5, pp 1-54.

(5) Syntheses of racemic slaframine: (a) Cartwright, D.; Gardiner, R. A.; Rinehart, K. L., Jr. *J. Am. Chem. Soc.* **1970**, 92, 7615. (b) Gensler, W. J.; Hu, M. W. *J. Org. Chem.* **1973**, 38, 3848. (c) Gobao, R. A.; Bremmer, M. L.; Weinreb, S. M. *J. Am. Chem. Soc.* **1982**, 104, 7065. (d) Schneider, M. J.; Harris, T. M. *J. Org. Chem.* **1984**, 49, 3681. (e) Dartmann, M.; Flitsch, W.; Krebs, B.; Pandl, K.; Westfechtel, A. *Liebigs Ann. Chem.* **1988**, 695. (f) Shono, T.; Matsumura, Y.; Katoh, S.; Takeuchi, K.; Sasaki, K.; Kamada, T.; Shimizu, R. *J. Am. Chem. Soc.* **1990**, 112, 2368. (g) Wasserman, H. H.; Vu, C. B. *Tetrahedron Lett.* **1994**, 52, 9779. Syntheses of (-)-slaframine: (h) Pearson, W. H.; Bergmeier, C. *J. Org. Chem.* **1991**, 56, 1976. (i) Choi, J. R.; Han, S.; Cha, J. K. *Tetrahedron Lett.* **1991**, 32, 6469. (j) Pearson, W. H.; Bergmeier, S. C. *J. Org. Chem.* **1992**, 57, 3977. (k) Sibi, M. P.; Christensen, J. W.; Li, B.; Renhowe, P. A. *J. Org. Chem.* **1992**, 57, 4329. (l) Knapp, S.; Gibson, F. S. *J. Org. Chem.* **1992**, 57, 4802. (m) Hua, D. H.; Park, J.; Katsuhira, T.; Bharathi, S. N. *J. Org. Chem.* **1993**, 58, 2144. (n) Knight, D. W.; Sibley, A. W. *Tetrahedron Lett.* **1993**, 34, 6607.

(6) For a previous five-step synthesis of **4** by alkylation of chiral glycolate imides, see: Cardillo, G.; Orena, M.; Romero, M.; Sandri, S. *Tetrahedron* **1989**, 45, 1501.

Scheme 3




when protection by the sterically demanding TIPS group⁹ was investigated. In this case, 48% of the 4-silyloxy derivative **9c** was isolated and only 7% of **10c** and 22% of **11c**.

For a functionalization of the unprotected HO-group, the synthetic intermediate **9c** was subjected to phthalimide under Mitsunobu conditions,¹⁰ giving the protected 1,3-diol **12a** in 98% yield (Scheme 3). Subsequent *N*-deprotection by hydrazinolysis afforded the primary amine **12b**. Removal of the TIPS group was accomplished under acidic conditions (HCl, MeOH) to give **12c** (combined yield for both deprotection steps: 91%). Thus, the method provides an efficient approach to chiral 1,3-diols. The enantiomeric integrity of the synthesis was established by derivatization of **12b** with (*S*)-1-phenylethyl isocyanate. Subsequent ¹H NMR studies of the urea **12d** including doping experiments with the diastereomer obtained by coupling of **12b** with (*R*)-1-phenylethyl isocyanate proved the synthetic material to be isomerically pure.

In analogy to our recent synthesis of enantiomerically pure epi- and diepislaframines **3a,b**,³ we envisioned to constructing the indolizidine skeleton by applying methodology developed by Wasserman.¹¹ Thus, treatment of the amino alcohol **12c** with the vinyl tricarbonyl reagent **13**¹² resulted in formation of the 3-hydroxypyrrole-2-carboxylate **14a** (Scheme 4). Activation of the terminal HO-group was performed by CBr₄/PPh₃ in CH₂Cl₂ to give the cyclization precursor **14b**. Subsequent deprotonation by NaH and intramolecular *C*-alkylation resulted in formation of the bicyclic β-keto esters **15a** and **15b** as a 1:2 mixture of diastereomers. According to diagnostic coupling constants of the ¹H NMR spectra, the six-membered rings of **15a** and **15b** adopt a chair conformation including an equatorial disposition of the benzyloxy substituent for **15a** and an axial orientation for **15b**. Since epimerization in position 8a was anticipated at a later step, both isomers were expected to be useful for the projected synthesis. Lewis acid assisted reduction of **15a,b** gave **16a,b**.¹³ Subsequently, hydrolysis and decarboxylation were induced by TFA to give a 10:1 mixture of the diastereomers **16c** and **16d**, independently whether **16a** or **16b** were reacted. According to the observations we have made for the reduction of **2**,³ reaction of the ketones **16c,d** with the sterically demanding reagent Li(*s*Bu)₃BH proceeded under complete *steric approach control*¹⁴ to yield **17a**, besides a small amount of its 8a-epimer, which was easily separable by flash

Scheme 4



chromatography. In contrast, reduction by NaBH₄/MeOH afforded a 1:1 mixture of **17a** and the diastereomer **17b**. *O*-Acetylation of **17a** and **17b** gave **18a** and **18b**, respectively. Hydrogenolytic debenzoylation of **18a** was accomplished using Pd/C as a catalyst to afford the didesoxycastanospermine derivative **19**. Finally, introduction of a nitrogen substituent at C-6 was investigated. Therefore, **19** was activated by trifluoromethanesulfonic anhydride and the resulting sulfonate was reacted with NaN₃. Instead of the projected inversion at C-6, we observed an equatorial disposition of the azide substituent of the main product **20a** and a rearranged structure for the minor product **21a**. We reason that this is due to an anchimeric participation of the endocyclic amine resulting in formation of an aziridinium salt. Nucleophilic ring opening of this intermediate by N₃⁻ explains the retention of configuration for **20a** and the skeletal migration of **21a**. Preferred formation of the rearranged isomer was observed under Mitsunobu conditions.¹⁰ Upon treatment of **19** with phthalimide/PPh₃ and DEAD, the pyrrolizidine **21b** was isolated in 55% yield, as well as 19% of **20b**. The stereochemistry of **20a** was estab-

(10) Mitsunobu, O. *Synthesis* **1981**, 1.
 (11) Wasserman, H. H.; Chi, B. V.; Cook, J. D. *Tetrahedron* **1992**, *48*, 2101.

(12) Compound **13** was prepared according to (a) Cooke, M. P., Jr.; Burman, D. L. *J. Org. Chem.* **1982**, *47*, 4955. (b) Wasserman, H. H.; Fukuyama, J.; Murugesan, N.; Van Duzer, J.; Lombardo, L.; McCarthy, K. J. *Am. Chem. Soc.* **1989**, *111*, 371.

(13) Comins, D. L.; LaMuyon, D. H. *Tetrahedron Lett.* **1989**, *30*, 5053.

(14) Dauben, W. G.; Fonken, G. J.; Noyce, D. S. *J. Am. Chem. Soc.* **1956**, *78*, 2579.

lished by catalytic hydrogenation to give 6-epislaframine ent-**3b** and subsequent transformation to the stable *N*-acetyl derivative **20c**. The spectral data were identical with those reported.^{3,5a} The pyrrolizidines **21a** and **21b** were transformed into the acetamide **21c**¹⁵ under standard conditions (H₂, Pd/C or hydrazine, then Ac₂O). In order to generate a "sflaframine-like" (*S*)-configuration at position 6 of the indolizidine skeleton, we envisioned oxidation of the secondary alcohol **19** followed by a diastereoselective reductive amination. Swern oxidation of **19** and subsequent treatment with H₂NOH gave the oxime **22**^{5b} (yield: 81%, isolated in a 3:1 mixture of *syn*/*anti*isomers), which could be transformed into *N*-acetylsflaframine (**23**)^{5h,i} according to the protocol reported by Gensler and co-workers for racemic material.^{5b}

Experimental Section

General. THF was distilled from Na/benzophenone and DMF and CH₂Cl₂ from CaH₂, in all cases immediately before use. All liquid reagents were also purified by distillation. Unless otherwise noted, reactions were conducted under dry N₂. Evaporations of final product solutions were done under vacuo with a rotatory evaporator. Flash chromatography was carried out with 230–400 mesh silica gel. Melting points are uncorrected. Methane was employed for CIMS. NMR spectra were recorded at 400 MHz; spectra were measured as CDCl₃ solutions using TMS as an internal standard. Unless specified otherwise, *J* values are given in hertz. NMR peak assignments are based on ¹H–¹H COSY and ¹H–¹³C COSY experiments.

Dimethyl (*R*)-2-(Benzyloxy)succinate (8). To a mixture of (*R*)-dimethyl malate (8.00 g, 49.3 mmol) and Ag₂O (16.9 g, 73.0 mmol), dissolved in EtOAc (150 mL), was slowly added benzyl bromide (8.65 mL, 73.0 mmol). The mixture was stirred for 15 h at rt. Then it was filtered, the solvent was evaporated, and the residue was purified by flash chromatography (petroleum ether: EtOAc, 85:15) to give **8** (8.02 g, 65%), [α]_D²³ +70° (*c* = 1.0, CHCl₃). For *ent*-**8**: lit.^{8a} [α]_D²³ –63° (CHCl₃, *c* = 1.6); lit.^{8b} [α]_D²³ –68.5° (*c* = 11.4, CHCl₃); IR (NaCl) (cm⁻¹) 1740; ¹H NMR δ 2.76–2.86 (m, 2H), 3.68 (s, 3H), 3.77 (s, 3H), 4.40 (dd, *J* = 7.3, 5.1, 1H), 4.54 (d, *J* = 11.0, 1H), 4.77 (d, *J* = 11.0, 1H), 7.27–7.35 (m, 5H); MS (CI) 253 (M + 1). Anal. Calcd for C₁₃H₁₆O₅: C, 61.89; H, 6.39. Found: C, 62.15; H, 6.14.

(*R*)-2-(Benzyloxy)butane-1,4-diol (4). To a solution of LiAlH₄ (40.6 mL, 1 M in THF) was added **8** (7.90 g, 31.2 mmol), dissolved THF (40 mL) at 0 °C. After 4 h, a saturated NaHCO₃ solution and Et₂O were added. The organic layer was separated, dried (MgSO₄), and evaporated to give pure **4** (6.05 g, 98%) as a semisolid substance: [α]_D²³ +15° (*c* = 1.0, CHCl₃), lit.⁶ [α]_D²³ +20.6° (*c* = 1.0, CHCl₃); ¹H NMR δ 1.78–1.94 (m, 2H), 2.26 (brs, 2H, OH), 3.61 (dd, *J* = 11.0, 3.7), 3.70–3.81 (m, 4H), 4.60 (d, *J* = 11.7, 1H), 4.64 (d, *J* = 11.7, 1H), 7.29–7.37 (m); MS (CI) 197 (M + 1), 105 (M – 91). Anal. Calcd for C₁₁H₁₆O₃: C, 67.32; H, 8.22. Found: C, 67.25; H, 8.28.

(*R*)-2-(Benzyloxy)-4-(*tert*-butyldimethylsiloxy)-1-butanol (9a), (*R*)-2-(Benzyloxy)-1-(*tert*-butyldimethylsiloxy)-1-butanol (10a), and (*R*)-2-(Benzyloxy)-1,4-(*tert*-butyldimethylsiloxy)butane (11a). To a mixture of **4** (150 mg, 0.76 mmol) and dimethyl-*tert*-butylchlorosilane (173 mg, 1.15 mmol) in DMF (20 mL) was added imidazole (156 mg, 2.29 mmol) at 0 °C. After 3 h, saturated NH₄Cl solution and Et₂O were added. The organic layer was dried (MgSO₄) and evaporated, and the residue was separated by flash chromatography (petroleum ether:EtOAc, 4:1) to give **11a** (46 mg, 15%), followed by a sparingly separable mixture of **9a** and **10a** (60 mg, 25%), **9a**: **10a** = 3:2). **11a**: colorless oil, [α]_D²³ +24° (*c* = 1.0, CHCl₃); ¹H NMR δ 0.06 (d, *J* = 6.6, 12H), 0.89 (d, *J* = 6.6, 18H), 1.63–1.71 (m, 1H), 1.73–1.81 (m, 1H), 3.61–3.77 (m, 5H), 4.57 (d, *J* = 11.7, 1H), 4.72 (d, *J* = 11.7, 1H), 7.26–7.31 (m, 2H), 7.33–7.36 (m,

4H); MS (CI) 425 (M + 1). Anal. Calcd for C₂₃H₄₄O₃Si₂: C, 64.88; H, 10.65. Found: C, 65.01; H, 10.53. **9a**: colorless oil; ¹H NMR δ 0.06 (s, 6H), 0.90 (s, 9H), 1.72–1.80 (m, 1H), 1.83–1.95 (m, 1H), 2.41 (t, *J* = 6.6, 1H, OH), 3.56–3.61 (m, 1H), 3.67–3.77 (m, 4H), 4.56 (d, *J* = 11.7, 1H), 4.61 (d, *J* = 11.7, 1H), 7.24–7.31 (m, 1H), 7.34–7.35 (m, 4H); MS (CI) 311 (M + 1), 279 (M – 31). Anal. Calcd for C₁₇H₃₀O₃Si: C, 65.76; H, 9.74. Found: C, 65.74; H, 10.02. **10a**: colorless oil; ¹H NMR δ 0.08 (s, 6H), 0.90 (s, 9H), 1.75–1.90 (m, 2H), 2.49 (t, *J* = 5.9, 1H, OH), 3.69–3.78 (m, 5H), 4.59 (d, *J* = 11.7, 1H), 4.73 (d, *J* = 11.7), 7.28–7.36 (m, 5H); MS (CI) 311 (M + 1), 279 (M – 31).

(*R*)-2-(Benzyloxy)-4-(*tert*-butyldiphenylsiloxy)-1-butanol (9b), (*R*)-2-(Benzyloxy)-1-(*tert*-butyldiphenylsiloxy)-4-butanol (10b), and (*R*)-2-(Benzyloxy)-1,4-(*tert*-butyldiphenylsiloxy)butane (11b). To a mixture of **4** (150 mg, 0.76 mmol) and *tert*-butyldiphenylchlorosilane (0.29 mL, 1.15 mmol) in DMF (20 mL) was added imidazole (156 mg, 2.29 mmol) at 0 °C. After 30 min, a saturated NH₄Cl solution and Et₂O were added. The organic layer was separated, dried (MgSO₄), and evaporated, and the residue was separated by flash chromatography (petroleum ether:EtOAc, 85:15), to give **11b** (143 mg, 27%), followed by **9b** and **10b** (160 mg, 48%, **9b**:**10b** 5:1). **11b**: colorless oil, [α]_D²³ +13° (*c* = 1.0); ¹H NMR δ 0.96 (s, 9H), 0.99 (s, 9H), 1.60–1.68 (m, 1H), 1.77–1.79 (m, 1H), 3.60 (dd, *J* = 10.3, 4.4, 1H), 3.66 (m, 1H), 3.71–3.79 (m, 3H), 4.40 (d, *J* = 11.7, 1H), 4.58 (d, *J* = 11.7, 1H), 7.16–7.22 (m, 3H), 7.23–7.36 (m, 1H), 7.55–7.65 (m, 8H); MS (CI) 595 (M – 78). Anal. Calcd for C₄₃H₅₂O₃Si₂: C, 76.74; H, 7.78. Found: C, 76.96; H, 7.57. **9b**: [α]_D²³ –2.5° (*c* = 1.0, CHCl₃); ¹H NMR δ 1.04 (s, 9H), 1.74–1.81 (m, 1H), 1.84–1.91 (m, 1H), 2.17 (t, *J* = 6.6, 1H, OH), 3.54–3.60 (m, 1H), 3.72–3.80 (m, 4H), 4.54 (d, *J* = 11.7, 1H), 4.58 (d, *J* = 11.7, 1H), 7.27–7.45 (m, 11H), 7.64–7.66 (m, 4H); MS (CI) 435 (M + 1). Anal. Calcd for C₂₇H₃₄O₃Si: C, 74.61; H, 7.89. Found: C, 74.77; H, 7.73. **10b**: ¹H NMR δ 1.00 (s, 9H), 1.67–1.79 (m, 2H), 2.23 (t, *J* = 5.1, 1H, OH), 3.61–3.74 (m, 5H), 4.42 (d, *J* = 11.7, 1H), 4.60 (d, *J* = 11.7, 1H), 7.21–7.37 (m, 11H), 7.57–7.62 (m, 4H).

(*R*)-2-(Benzyloxy)-4-(triisopropylsiloxy)-1-butanol (9c), (*R*)-2-(Benzyloxy)-1-(triisopropylsiloxy)-4-butanol (10c), and (*R*)-2-(Benzyloxy)-1,4-(triisopropylsiloxy)butane (11c). A mixture of **4** (14.5 g, 74 mmol), triisopropylchlorosilane (17.4 mL, 81.0 mmol), and imidazole (11.0 g, 160 mmol) in DMF (300 mL) was stirred at rt for 4 h. Then, a saturated NH₄Cl solution and Et₂O were added. The organic layer was separated, dried (MgSO₄), and evaporated, and the residue was separated by flash chromatography (petroleum ether:EtOAc, 9:1), to give **11c** (8.28 g, 22%), followed by **9c** (12.5 g, 48%) and **10c** (1.90 g, 7%). **11c**: colorless oil, [α]_D²³ +20° (*c* = 1.2, CHCl₃); ¹H NMR δ 1.04 (s, 6H), 1.06 (s, 36H), 1.65–1.73 (m, 1H), 1.79–1.87 (m, 1H), 3.68–3.76 (m, 2H), 3.77–3.83 (m, 3H), 4.59 (d, *J* = 11.7, 1H), 4.75 (d, *J* = 11.7, 1H), 7.25–7.31 (m, 1H), 7.31–7.36 (m, 4H); MS (CI) 509 (M + 1), 465 (M – 43), 335 (M – 173). Anal. Calcd for C₂₅H₅₆O₃Si: C, 68.44; H, 11.09. Found: C, 68.38; H, 11.16. **9c**: colorless oil, [α]_D²³ +2.8° (*c* = 0.8, CHCl₃); ¹H NMR δ 1.05 (s, 3H), 1.07 (s, 18H), 1.77–1.82 (m, 1H), 1.87–1.92 (m, 1H), 2.44 (t, *J* = 5.8, 1H, OH), 3.58–3.63 (m, 1H), 3.72–3.78 (m, 2H), 3.78–3.87 (m, 2H), 4.57 (d, *J* = 11.7, 1H), 4.63 (d, *J* = 11.7, 1H), 7.26–7.31 (m, 1H), 7.35 (d, *J* = 4.4, 4H); MS (CI) 353 (M + 1), 261 (M – 91). Anal. Calcd for C₂₀H₃₆O₃Si: C, 68.13; H, 10.29. Found: C, 68.16; H, 10.26. **10c**: ¹H NMR δ 0.99 (s, 3H), 1.00 (s, 18H), 1.64–1.75 (m, 1H), 1.75–1.87 (m, 1H), 2.38 (t, *J* = 6.6, 1H, OH), 3.61–3.80 (m, 5H), 4.54 (d, *J* = 11.7, 1H), 4.68 (d, *J* = 11.7, 1H), 7.21–7.25 (m, 1H), 7.28 (d, *J* = 4.4, 4H).

(*R*)-*N*-(2-(Benzyloxy)-4-(triisopropylsiloxy)butyl)-phthalimide (12a). Diethyl azodicarboxylate (6.50 mL, 14 mmol, 38% solution in toluene) was added dropwise to a mixture of **9c** (5.01 g, 14.0 mmol), phthalimide (2.09g, 14.0 mmol), and triphenylphosphine (3.73 g, 14.0 mol) in THF (100 mL). The mixture was stirred for 16 h. Then, the solvent was evaporated, and the residue was purified by flash chromatography (CH₂Cl₂: petroleum ether, 3:2) to give **12a** (8.8 g, 98%) as a colorless oil: [α]_D²³ +5.3° (*c* = 1.0, CHCl₃); IR (NaCl) (cm⁻¹) 1774, 1720; ¹H NMR δ 1.02 (s, 3H), 1.04 (s, 18H), 1.75–1.83 (m, 2H), 3.76–3.89 (m, 4H), 3.96–4.02 (m, 1H), 4.57 (d, *J* = 11.7, 1H), 4.60 (d, *J* = 11.7, 1H), 7.08–7.16 (m, 3H); 7.22–7.25 (m, 2H), 7.68 (dd, *J* = 5.1, 2.9, 2H), 7.79 (dd, *J* = 5.1, 2.9, 2H); MS (CI) 482 (M +

(15) The spectroscopic data of **21c** are very similar to those reported and observed for **23**. Structure determination is based on ¹H–¹H COSY and ¹H–¹³C COSY experiments and mass spectroscopy. Diagnostic for **21c** is a ³*J* coupling between the NH and neighboring CH₂ protons as well as a characteristic α-cleavage of a CH₂NHAc fragment (see Experimental Section).

1), (EI) 439 (M - 43), 304 (M - 177). Anal. Calcd for C₂₈H₃₉NO₄Si: C, 69.82; H, 8.16; N, 2.91. Found: C, 69.58; H, 8.39; N, 2.93.

(R)-2-Benzoyloxy-4-triisopropylsiloxy-1-butylamine (12b).

A solution of **12a** (11.4 g, 24.0 mmol) and hydrazine hydrate (11.5 mL, 238 mmol) in EtOH was refluxed for 16 h. The solvent was then removed, and saturated NaHCO₃ solution was added. After extraction with Et₂O, the organic layer was dried (MgSO₄) and evaporated to leave pure **12b** (7.9 g, 95%) as a colorless oil: [α]_D²³ +4.8° (c = 1.9, CHCl₃); ¹H NMR δ 1.05 (s, 3H), 1.06 (s, 18H), 1.68–1.76 (m, 1H), 1.81–1.88 (m, 1H), 2.74 (dd, J = 13.2, 4.4, 1H), 2.91 (dd, J = 13.2, 6.6, 1H), 3.59–3.65 (m, 1H), 3.77–3.85 (m, 2H), 4.55 (d, J = 11.7, 1H), 4.60 (d, J = 11.7, 1H), 7.27–7.35 (m, 5H); MS (CI) 352 (M + 1), 308 (M - 43), 178 (M - 173). Anal. Calcd for C₂₀H₃₇NO₂Si: C, 68.32; H, 10.61; N, 3.98. Found: C, 68.36; H, 10.31; N, 4.24.

Determination of the Enantiomeric Purity of 12b. To a stirred solution of **12b** (28 mg, 0.08 mmol) in THF (2 mL) was added (S)-1-phenylethyl isocyanate (11.2 μL, 0.08 mmol) at 0 °C. After 1 h, the solvent was evaporated to give **12d** (40 mg, 100%) as a colorless oil: [α]_D²³ +1.6° (c = 1.0, CHCl₃); IR (NaCl) (cm⁻¹) 1630; ¹H NMR δ 1.03 (s, 3H), 1.04 (s, 18H), 1.36 (d, J = 6.6, 3H), 1.64–1.71 (m, 1H), 1.74–1.82 (m, 1H), 3.19 (dt, J = 13.9, 5.9, 1H), 3.36–3.42 (m, 1H), 3.58–3.68 (m, 1H), 3.73–3.80 (m, 2H), 4.40 (d, J = 11.7, 1H), 4.50 (d, J = 11.7, 1H), 4.62–4.63 (m, 1H, NH), 4.71–4.77 (m, 1H), 4.86 (bs, 1H, NH), 7.18–7.35 (m, 10H); MS (CI) 499 (M + 1), 455 (M - 43). Anal. Calcd for C₂₈H₄₆N₂O₃: C, 67.43; H, 9.30; N, 5.62. Found: C, 67.63; H, 9.11; N, 5.60. Coupling using (R)-phenylethyl isocyanate under the same conditions gave the *like*-diastereomer in 94% yield: [α]_D²³ +7.2° (c = 1.0, CHCl₃); IR (NaCl) (cm⁻¹) 1630; ¹H NMR δ 1.03 (s, 3H), 1.05 (s, 18H), 1.38 (d, J = 6.8, 3H), 1.62–1.73 (m, 2H), 3.19 (dt, J = 14.1, 6.0, 1H), 3.39 (ddd, J = 13.7, 5.5, 3.8), 3.66–3.71 (m, 1H), 3.72–3.78 (m, 2H), 4.47 (d, J = 12.0, 1H), 4.53 (d, J = 12.0, 1H), 4.65 (bs, 1H, NH), 4.68–4.75 (m, 1H), 4.85 (bs, 1H, NH), 7.21–7.33 (m, 10H); MS (CI) 499 (M + 1), 455 (M - 43). Anal. Calcd for C₂₈H₄₆N₂O₃Si: C, 67.43; H, 9.30; N, 5.62. Found: C, 67.58; H, 9.17; N, 5.58.

(R)-4-Amino-3-benzoyloxy-1-butanol (12c). Compound **12b** (9.9 g, 28.0 mmol) was refluxed in a 1:3 mixture of 2 N HCl and EtOH (200 mL) for 15 min. After being cooled to rt, the solvent was evaporated and a saturated NaCl solution and Et₂O were added. The aqueous phase was basified with 2 N NaOH and again extracted with Et₂O. The organic layer was dried (MgSO₄) and the solvent was evaporated to leave pure **12c** (5.2 g, 96%) as a colorless oil: [α]_D²³ -7° (c = 1.0, CHCl₃); ¹H NMR δ 1.85–1.89 (m, 1H), 1.90–1.97 (m, 1H), 2.28 (bs, 2H, NH₂), 2.78 (dd, J = 12.5, 3.7, 1H), 3.04 (dd, J = 12.5, 5.1, 1H), 3.61–3.38 (m, 2H), 3.76–3.82 (m, 1H), 4.53 (d, J = 11.7, 1H), 4.58 (d, J = 11.7, 1H), 7.29–7.38 (m, 5H); MS (CI) 196 (M + 1). Anal. Calcd for C₁₁H₁₇NO₂: C, 67.66; H, 8.78; N, 7.17. Found: C, 67.46; H, 9.01; N, 7.14.

(R)-tert-Butyl 1-(2-(Benzoyloxy)-4-hydroxybutyl)-3-hydroxypropanoate (14a). A mixture of **12c** (0.35 g, 1.79 mmol) and **13** (0.36 g, 1.79 mmol) in CH₂Cl₂ (20 mL) was stirred at rt for 30 min. After addition of silica gel (2.7 g), it was stirred for another 16 h. Then, the solution was filtered, the solvent was removed, and the residue was purified by flash chromatography (petroleum ether:EtOAc, 7:3) to give **14a** (0.33 g, 51%) as a colorless oil: [α]_D²³ -73° (c = 1.0, CHCl₃); IR (NaCl) (cm⁻¹) 1700, 1640; ¹H NMR (MeOD) δ 1.56 (s, 9H), 1.60–1.67 (m, 1H), 1.68–1.77 (m, 1H), 3.61–3.71 (m, 2H), 3.80–3.86 (m, 1H), 3.93–3.99 (m, 1H), 4.00 (d, J = 11.1, 1H), 4.21 (d, J = 11.1, 1H), 4.32 (dd, J = 13.7, 3.0, 1H), 5.71 (d, J = 3.0, 1H), 6.74 (d, J = 3.0, 1H), 7.14 (dd, J = 7.7, 1.7, 2H), 7.23–7.29 (m, 3H); MS (CI) 362 (M + 1). Anal. Calcd for C₂₀H₂₇NO₅: C, 66.62; H, 7.53; N, 3.88. Found: C, 66.53; H, 7.94; N, 3.51.

(R)-tert-Butyl 1-(2-(Benzoyloxy)-4-bromobutyl)-3-hydroxypropanoate (14b). To a solution of **14a** (0.77 g, 2.14 mmol) and tetrabromomethane (0.886 g, 2.670 mmol) in CH₂Cl₂ (20 mL) was slowly added triphenylphosphine (0.840 g, 4.272 mmol) at rt. After 30 min, the solvent was evaporated and the residue was purified by flash chromatography (petroleum ether:EtOAc, 93:7) to give **14b** (0.8 g, 88%) as a colorless solid: mp 88 °C; [α]_D²³ -39° (c = 0.9, CHCl₃); IR (KBr) (cm⁻¹) 1640, 1550; ¹H NMR (MeOD) δ 1.59 (s, 9H), 1.92–1.97 (m, 2H), 3.47–3.55 (m, 2H), 3.92–4.01 (m, 2H), 3.99 (d, J = 11.0, 1H), 4.17 (d, J = 11.0, 1H), 4.34 (dd, J = 12.9, 2.1, 1H), 5.73 (d, J =

2.9, 1H), 6.75 (d, J = 2.9, 1H), 7.18 (dd, J = 8.1, 2.2, 2H), 7.24–7.30 (m, 3H); MS (EI) 367 (M - 57), 243 (M - 181). Anal. Calcd for C₂₀H₂₆NO₄Br: C, 56.61; H, 6.18; N, 3.30. Found: C, 56.58; H, 6.37; N, 3.18.

(6R,8aS)-tert-Butyl-6-(Benzoyloxy)-5,6,7,8-tetrahydro-1-oxo-8a(1H)-indolizinecarboxylate (15a) and (6R,8aR)-tert-Butyl-6-(Benzoyloxy)-5,6,7,8-tetrahydro-1-oxo-8a(1H)-indolizinecarboxylate (15b). To a suspension of sodium hydride (0.14 g, 6.00 mmol) in THF (40 mL) was slowly added a solution of **14b** (1.16 g, 2.73 mmol) in THF (20 mL) at 0 °C. When the production of hydrogen ceased, the mixture was stirred for 30 min at 40 °C. After addition of a saturated NH₄Cl solution, the product was extracted with ether, and the organic layer was dried (MgSO₄) and evaporated. The residue was separated by flash chromatography (petroleum ether:EtOAc, 4:1) to give **15a** (0.62 g, 65%) followed by **15b** (0.27 g, 28%). **15a** (colorless solid); mp 110 °C; [α]_D²³ +382° (c = 0.95, CHCl₃); IR (KBr) (cm⁻¹) 1730, 1660, 1540; ¹H NMR δ 1.40 (s, 9H, t-Bu), 1.50 (tt, J = 13.7, 3.0, 1H, 7-H_{ax}), 1.82 (dt, J = 13.7, 3.4, 1H, 8-H_{ax}), 1.96–2.02 (m, 1H, 7-H_{eq}), 2.38 (dt, J = 13.3, 3.4, 1H, 8-H_{eq}), 3.38 (dd, J = 13.7, 2.1, 1H, 5-H_{ax}), 3.55–3.61 (m, 2H, 5-H_{eq} + 6-H_{eq}), 4.36 (d, J = 12.0, 1H, OCH₂Ph), 4.48 (d, J = 12.0, 1H, OCH₂Ph), 4.93 (d, J = 3.0, 1H, 2-H), 7.19–7.27 (m, 5H, H_{ar}), 7.65 (d, J = 3.0, 1H, 3-H); ¹³C NMR δ 24.8, 25.5, 27.9, 51.2, 70.2, 72.0, 73.1, 82.7, 94.7, 127.3, 127.7, 128.5, 138.0, 165.0, 165.3, 198.3; MS (CI) 344 (M + 1), 288 (M - 57, tBu). Anal. Calcd for C₂₀H₂₅NO₄: C, 69.95; H, 7.34; N, 4.08. Found: C, 69.83; H, 7.68; N, 3.86. **15b** (yellowish solid); mp. 122 °C; [α]_D²³ -273° (c = 0.9, CHCl₃); IR (KBr) (cm⁻¹) 1730, 1660, 1540; ¹H NMR; δ(ppm) 1.42–1.47 (m, 1H, 8-H_{ax}), 1.47 (s, 9H, COOtBu), 1.47–1.49 (m, 1H, 7-H_{ax}), 2.18–2.22 (m, 1H, 7-H_{eq}), 2.71 (dt, J = 12.4, 3.0, 1H, 8-H_{eq}), 3.23 (dd, J = 12.8, 10.3, 1H, 5-H_{ax}), 3.38–3.46 (m, 1H, 6-H_{ax}), 3.78 (ddd, J = 12.4, 5.1, 1.7, 1H, 5-H_{eq}), 4.53 (d, J = 11.5, 1H, OCH₂Ph), 4.62 (d, J = 11.5, 1H, OCH₂Ph), 4.96 (d, J = 3.0, 1H, 2-H), 7.31–7.39 (m, 5H, H_{ar}), 7.75 (d, J = 3.0, 1H, 3-H); MS (CI) 344 (M + 1), 388 (M - 57). Anal. Calcd for C₂₀H₂₅NO₄: C, 69.95; H, 7.34; N, 4.08. Found: C, 69.93; H, 7.57; N, 4.06.

(6R,8aS)-tert-Butyl 6-(Benzoyloxy)-2,3,5,6,7,8-hexahydro-1-oxo-8a(1H)-indolizinecarboxylate (16a). To a solution of **15a** (0.95 g, 2.76 mmol) in THF (100 mL) was added BF₃·Et₂O (0.44 mL, 3.59 mmol) at -78 °C. After 5 min, LiEt₃BH (Super Hydride, 1 M in THF, 3.58 mL) was added and stirring was continued for 1 h. Then, a saturated NaCl solution and a saturated NaHCO₃ solution were added. After extraction with Et₂O, the organic layer was dried (MgSO₄) and evaporated. The residue was purified by flash chromatography (petroleum ether:EtOAc 4:1) to give **16a** (0.72 g, 76%) as a colorless oil: [α]_D²³ +59° (c = 1.0, CHCl₃); IR (NaCl) (cm⁻¹) 1760, 1720; ¹H NMR δ 1.46 (s, 9H, COOtBu), 1.61–1.72 (m, 1H, 7-H_{ax}), 1.82 (dt, J = 13.7, 4.7, 1H, 8-H_{ax}), 2.0–2.1 (m, 2H, 7-H_{eq} + 8-H_{eq}), 2.48 (t, J = 6.4, 2-H₂), 3.11–3.17 (m, 2H, 5-H₂), 3.32–3.37 (m, 1H, 3-H), 3.40–3.45 (m, 1H, 3-H), 3.52 (bs, 1H, 6-H_{eq}), 4.52 (d, J = 12.4, 1H, OCH₂Ph), 4.58 (d, J = 12.4, 1H, OCH₂Ph), 7.27–7.34 (m, 5H, H_{ar}); MS (CI) 346 (M + 1), 244 (M - 101). Anal. Calcd for C₂₀H₂₇NO₄: C, 69.54; H, 7.88; N, 4.06. Found: C, 69.62; H, 7.76; N, 4.08.

(6R,8aR)-tert-Butyl 6-(Benzoyloxy)-2,3,5,6,7,8-hexahydro-1-oxo-8a(1H)-indolizinecarboxylate (16b). Compound **15b** (0.40 g, 1.18 mmol), BF₃·Et₂O (0.19 mL, 1.52 mmol), and LiEt₃BH (Super Hydride, 1 M in THF, 1.52 mL, 1.52 mmol) were reacted and worked up as described for **16a** to give **16b** (0.32 g, 80%) as a colorless solid: mp 49 °C; [α]_D²³ -86° (c = 1.0, CHCl₃); IR (NaCl) (cm⁻¹) 1760, 1720; ¹H NMR δ 1.33 (dt, J = 13.3, 3.4, 1H, 8-H_{ax}), 1.45–1.52 (m, 1H, 7-H_{ax}), 1.46 (s, 9H, COOtBu), 2.10–2.14 (m, 1H, 7-H_{eq}), 2.33 (dt, J = 13.3, 3.4, 1H, 8-H_{eq}), 2.45–2.50 (m, 2H, 2-H₂), 2.90 (dd, J = 11.5, 10.3, 1H, 5-H_{ax}), 3.09–3.14 (m, 1H, 3-H), 3.18 (ddd, J = 12.0, 5.1, 1.7, 1H, 5-H_{eq}), 3.38–3.43 (m, 1H, 3-H), 3.51–3.57 (m, 1H, 6-H_{ax}), 4.55 (d, J = 12.0, 1H, OCH₂Ph), 4.60 (d, J = 12.0, 1H, OCH₂Ph), 7.27–7.31 (m, 1H, H_{ar,p}), 7.32–7.34 (m, 4H, H_{ar,o+m}); ¹³C NMR (CDCl₃) 26.5, 27.8, 28.1, 36.0, 46.2, 51.1, 70.5, 71.2, 72.5, 82.5, 127.5, 127.6, 128.4, 138.5, 168.0, 209.0; MS (EI) 244 (M - 101). Anal. Calcd for C₂₀H₂₇NO₄: C, 69.54; H, 7.88; N, 4.06. Found: C, 69.60; H, 7.92; N, 3.95.

(6R,8aS)-6-(Benzoyloxy)-2,3,6,7,8,8a-hexahydro-5(1H)-indolizine (16c) and (6R,8aR)-6-(Benzoyloxy)-2,3,6,7,8,8a-hexahydro-5(1H)-indolizine (16d). TFA (9.57 mL, 0.12 mol) was added dropwise to a solution of **16a** or **16b** (0.72 g,

2.08 mmol) in CH_2Cl_2 (30 mL). The mixture was stirred for 3 h and then cooled to 0 °C, when saturated NaHCO_3 solution was added. After extraction with Et_2O , the organic layer was dried (MgSO_4) and evaporated. The residue was purified by flash chromatography (petroleum ether:EtOAc, 65:35), to give a mixture of **16c** and **16d** (0.43 g, 85% **16c:16d** = 10:1): $^1\text{H NMR}$ (major isomer) δ 1.16–1.30 (m, 2H, 7- H_{ax} + 8- H_{ax}), 1.95 (m, 1H, 8- H_{eq}), 2.06–2.11 (m, 1H, 8a-H), 2.07 (dd, J = 10.4, 9.8, 1H, 5- H_{ax}), 2.16–2.19 (m, 1H, 7- H_{eq}), 2.27–2.31 (m, 2H, 2- H_2), 2.47 (q, J = 8.6, 1H, 3-H), 3.15–3.20 (m, 1H, 3-H), 3.34 (ddd, J = 10.3, 4.7, 1.3, 1H, 5- H_{eq}), 3.46–3.53 (m, 1H, 6-H), 4.50 (d, J = 11.5, 1H, OCH_2Ph), 4.54 (d, J = 11.5, 1H, OCH_2Ph), 7.19–7.29 (m, 5H, H_{ar}); $^{13}\text{C NMR}$ (major isomer) δ 23.5 ($\text{H}_2\text{C}-8$), 30.2 ($\text{H}_2\text{C}-7$), 36.5 ($\text{H}_2\text{C}-2$), 49.4 ($\text{H}_2\text{C}-3$), 57.8 ($\text{H}_2\text{C}-5$), 68.7 (HC-8a), 70.8 (OCH_2Ph), 74.1 (HC-6), 127.5 (OCH_2Ph : $\text{HC}_{\text{ar,p}}$), 127.6 (OCH_2Ph : $\text{HC}_{\text{ar,m}}$), 128.4 (OCH_2Ph : $\text{HC}_{\text{ar,o}}$), 138.4 (OCH_2Ph : $\text{C}_{\text{ar,i}}$), 212.8 (C-1); MS (CI) 246 (M + 1), 138 (M - 107). Anal. Calcd for $\text{C}_{15}\text{H}_{19}\text{NO}_2$: C, 73.44; H, 7.81; N, 5.71. Found: C, 73.29; H, 7.96; N, 5.61.

(1S,6R,8aS)-6-(Benzyloxy)-1,2,3,5,6,7,8,8a-octahydro-1-indolizinole (17a) and (1R,6R,8aS)-6-(Benzyloxy)-1,2,3,5,6,7,8,8a-octahydro-1-indolizinole (17b). **A.** To a solution of crude **16c,d** (80 mg, 0.33 mmol) in MeOH (10 mL) was added NaBH_4 (12.4 mg, 0.33 mmol) at 0 °C. After the solution was stirred for 1 h, 2 N HCl (1 mL) was added, followed by addition of a saturated NaHCO_3 solution and Et_2O . The organic layer was separated, dried (MgSO_4), and evaporated, and the residue was separated by flash chromatography (CH_2Cl_2 :MeOH, 95:5) to give **17a** (34 mg, 42%) followed by **17b** (34 mg, 42%) both as colorless oils.

B. To a solution of crude **16c,d** (0.42 g, 1.7 mmol) in THF (70 mL) was added $\text{Li}(\text{sBu})_3\text{BH}$ (L-Selectride, 1 M in THF, 1.87 mL) at -78 °C. After the solution was stirred for 30 min at -78 °C, a saturated NaHCO_3 solution was added and the mixture was extracted with Et_2O . The organic layer was dried (MgSO_4) and evaporated and the residue purified by flash chromatography (CH_2Cl_2 :MeOH, 9:1) to yield **17a** (0.28 g, 66%) and in small amounts the 8a-epimer, derived from **16d** (0.04 g, 8%), both as colorless oils. **17a**: $[\alpha]_D^{25} + 41^\circ$ (c = 1.0, CHCl_3); $^1\text{H NMR}$ δ 1.20–1.30 (m, 1H), 1.44–1.54 (m, 1H), 1.62–1.74 (m, 3H), 1.84 (dd, J = 10.3, 9.8, 1H), 2.01 (q, J = 8.9, 1H), 2.09–2.18 (m, 2H), 3.02 (dt, J = 8.9, 2.1, 1H), 3.33 (ddd, J = 10.3, 4.3, 1.7, 1H), 3.46–3.53 (m, 1H), 3.99 (bs, 1H), 4.49 (d, J = 12.0, 1H), 4.53 (d, J = 12.0, 1H), 7.19–7.27 (m, 5H); MS (CI) 248 (M + 1), 228 (M - 19), 140 (M - 107). Anal. Calcd for $\text{C}_{15}\text{H}_{21}\text{NO}_2$: C, 72.84; H, 8.56; N, 5.66. Found: C, 72.84; H, 8.61; N, 5.62. **17b**: $[\alpha]_D^{25} - 8^\circ$ (c = 0.4, CHCl_3); $^1\text{H NMR}$ δ 1.20–1.27 (m, 2H), 1.54–1.62 (m, 1H), 1.83–1.87 (m, 1H), 1.99–2.06 (m, 1H), 2.01 (dd, J = 10.3, 9.8, 1H), 2.18–2.21 (m, 1H), 2.26–2.33 (m, 1H), 2.45 (q, J = 8.9, 1H), 2.95 (dt, J = 8.9, 2.1, 1H), 3.30 (ddd, J = 10.3, 4.6, 1.2, 1H), 3.50–3.58 (m, 1H), 3.87–3.92 (m, 1H), 4.55 (d, J = 12.0, 1H), 4.58 (d, J = 12.0, 1H), 7.25–7.30 (m, 1H), 7.31–7.34 (m, 4H). Anal. Calcd for $\text{C}_{15}\text{H}_{21}\text{NO}_2$: C, 72.84; H, 8.56; N, 5.66. Found: C, 73.34; H, 8.45; N, 5.26. **(1S,6S,8aR)-epimer**: $[\alpha]_D^{25} - 16^\circ$ (c = 1.0, CHCl_3); $^1\text{H NMR}$ δ 1.30–1.38 (m, 1H), 1.58–1.68 (m, 1H), 1.71–1.76 (m, 2H), 1.88–1.99 (m, 2H), 2.05–2.18 (m, 3H), 3.14 (dt, J = 8.9, 2.5, 1H), 3.32 (dt, J = 11.9, 2.1, 1H), 3.59–3.61 (m, 1H), 4.06 (bs, 1H), 4.53 (d, J = 12.4, 1H), 4.62 (d, J = 12.4, 1H), 7.26–7.28 (m, 1H), 7.29–7.38 (m, 4H); MS (CI) 248 (M + 1). Anal. Calcd for $\text{C}_{15}\text{H}_{21}\text{NO}_2$: C, 72.84; H, 8.56; N, 5.66. Found: C, 72.63; H, 8.91; N, 5.52.

(1S,6R,8aS)-6-(Benzyloxy)-1,2,3,5,6,7,8,8a-octahydroindoliziny Acetate (18a). Compound **17a** (0.29 g, 1.18 mmol) was dissolved in pyridine (3 mL). After addition of Ac_2O (3 mL), the mixture was stirred for 4 h at rt. The reaction mixture was evaporated, and the residue was purified by flash chromatography (petroleum ether:EtOAc, 2:3), to give **18a** (0.31 g, 90%) as a colorless oil: $[\alpha]_D^{25} + 4^\circ$ (c = 1.0, CHCl_3); IR (NaCl) (cm^{-1}) 1730; $^1\text{H NMR}$ δ 1.18–1.29 (m, 1H), 1.34–1.44 (m, 1H), 1.64–1.70 (m, 1H), 1.71–1.77 (m, 1H), 1.79–1.87 (m, 1H), 1.82 (dd, J = 10.25, 9.8, 1H), 1.98 (s, 3H), 2.05 (q, J = 9.0, 1H), 2.08–2.15 (m, 1H), 2.18–2.27 (m, 1H), 3.05 (dt, J = 9.0, 1.7, 1H), 3.39 (ddd, J = 10.25, 4.7, 1.7, 1H), 3.47–3.55 (m, 1H), 4.49 (d, J = 12.0, 1H), 4.52 (d, J = 12.0, 1H); 5.11–5.14 (m, 1H); 7.17–7.23 (m, 1H), 7.24–7.26 (m, 4H); MS (CI) 290 (M + 1), 230 (M - 59), 182 (M - 107). Anal. Calcd for $\text{C}_{17}\text{H}_{23}\text{NO}_3$: C, 70.56; H, 8.01; N, 4.84. Found: C, 70.28; H, 7.84; N, 5.29.

(1R,6R,8aS)-6-(Benzyloxy)-1,2,3,5,6,7,8,8a-octahydroindoliziny Acetate (18b). Compound **17b** (27 mg, 0.11 mmol) was reacted and worked up as described for **18a** to give **18b** (23 mg, 88%) as a colorless solid: mp 27 °C; $[\alpha]_D^{25} - 18^\circ$ (c = 1.0, CHCl_3); IR (KBr) (cm^{-1}) 1740; $^1\text{H NMR}$ δ 1.17–1.29 (m, 2H), 1.49–1.57 (m, 2H), 1.88–1.96 (m, 2H), 1.98 (s, 3H), 2.09–2.13 (m, 1H), 2.23–2.38 (m, 2H), 2.86–2.90 (m, 1H), 3.27 (ddd, J = 10.25, 4.7, 1.7, 1H), 3.44–3.51 (m, 1H), 4.48 (d, J = 12.0, 1H); 4.52 (d, J = 12.0, 1H), 4.64–4.69 (m, 1H), 7.18–7.26 (m, 5H). Anal. Calcd for $\text{C}_{17}\text{H}_{23}\text{NO}_3$: C, 70.56; H, 8.01; N, 4.84. Found: C, 70.21; H, 7.86; N, 4.31.

(1S,6R,8aS)-6-Hydroxy-1,2,3,5,6,7,8,8a-octahydroindoliziny Acetate (19). A mixture of **18a** (0.31 g, 1.07 mmol) and Pd/C (10%, 0.16 g) in AcOH (20 mL) was stirred for 16 h under a balloon of hydrogen. After filtration, the filtrate was evaporated. The residue was dissolved in a saturated NaHCO_3 solution and extracted with CH_2Cl_2 . The organic layer was dried and evaporated to give **19** (0.19 g, 88%) as a yellowish oil: $[\alpha]_D^{25} + 7.5^\circ$ (c = 0.95, CHCl_3); IR (NaCl) (cm^{-1}) 3390, 1730; $^1\text{H NMR}$ δ 1.15–1.25 (m, 1H), 1.39–1.49 (m, 1H), 1.64–1.70 (m, 1H), 1.64–1.75 (m, 1H), 1.78 (dd, J = 10.3, 10.3, 1H), 1.81–1.86 (m, 1H), 1.90–2.16 (m, 2H), 1.99 (s, 3H), 2.17–2.29 (m, 1H), 3.07 (dt, J = 9.0, 1.7, 1H), 3.28 (ddd, J = 10.3, 4.7, 1.7, 1H), 3.74–3.81 (m, 1H), 5.12–5.16 (m, 1H); MS (CI) 200 (M + 1), 140 (M - 59). Anal. Calcd for $\text{C}_{16}\text{H}_{21}\text{NO}_3$: C, 60.28; H, 8.60; N, 7.03. Found: C, 60.88; H, 8.53; N, 6.50.

(1S,6R,8aS)-6-Azido-1,2,3,5,6,7,8,8a-octahydroindoliziny Acetate (20a) and (1S,5S,7aS)-5-Azidomethyl-2,3,5,6,7,7a-hexahydro-1(1H)-pyrroliziny Acetate (21a). To a solution of **19** (86 mg, 0.43 mmol) and triethylamine (71 μL , 0.51 mmol) in CH_2Cl_2 (10 mL) was added dropwise a solution of trifluoromethanesulfonic anhydride (70.3 μL , 0.47 mmol) in CH_2Cl_2 (1 mL) at 0 °C. The solution was stirred for 2 h. Then, a suspension of NaN_3 (200 mg) in DMF (10 mL) was added. After 1 h, a saturated NH_4Cl solution and Et_2O were added. The organic layer was separated, dried (MgSO_4), and evaporated, and the residue was purified by flash chromatography (petroleum ether:EtOAc, 1:1), to give **20a** (38 mg, 40%), followed by **21a** (10 mg, 11%). **20a** (colorless oil): $[\alpha]_D^{25} - 6.5^\circ$ (c = 1, CHCl_3); IR (NaCl) (cm^{-1}) 2100, 1740; $^1\text{H NMR}$ δ 1.29–1.39 (m, 1H), 1.47–1.57 (m, 1H), 1.76–1.85 (m, 2H), 1.87–1.94 (m, 1H), 1.91 (dd, J = 10.3, 9.7, 1H), 2.07 (s, 3H), 2.07–2.18 (m, 1H), 2.13 (q, J = 9.0, 1H), 2.27–2.36 (m, 1H), 3.16 (dt, J = 9.0, 1.7, 1H), 3.34 (ddd, J = 10.3, 4.3, 1.7, 1H), 3.48–3.55 (m, 1H), 5.20–5.24 (m, 1H); MS (CI) 225 (M + 1), 182 (M - 42). **21a**: $[\alpha]_D^{25} - 47^\circ$ (c = 0.7, CHCl_3); IR (NaCl) (cm^{-1}) 2100, 1740; $^1\text{H NMR}$ δ 1.63–1.81 (m, 3H), 2.02–2.35 (m, 3H), 2.08 (s, 3H), 2.69 (dt, J = 10.3, 6.4, 1H), 2.83–2.89 (m, 1H), 3.18–3.27 (m, 2H), 3.24 (dd, J = 6.0, 2.1, 1H), 3.72–3.77 (m, 1H, 6-H), 5.11–5.14 (m, 1H, 1-H); MS (CI) 225 (M + 1), 182 (M - 42).

(1S,6R,8aS)-6-(Phthalimido)-1,2,3,5,6,7,8,8a-octahydroindoliziny Acetate (20b) and (1S,5S,8aS)-5-(Phthalimido)-methyl-2,3,5,6,7,7a-hexahydro-1(1H)-pyrroliziny Acetate (21b). To a solution of **19** (56 mg, 0.28 mmol), phthalimide (41 mg, 0.28 mmol), and triphenylphosphine (74 mg, 0.28 mmol) in THF (5 mL) was slowly added diethyl azodicarboxylate (38% in toluene, 128 μL , 0.28 mmol). After 16 h, the solvent was evaporated and the residue was purified by flash chromatography (CH_2Cl_2 :MeOH, 95:5) to give **20b** (17.7 mg, 27%) and **21b** (34.7 mg, 55%). **20b**: $[\alpha]_D^{25} - 6^\circ$ (c = 0.75, CHCl_3); $^1\text{H NMR}$ δ 1.58–1.68 (m, 1H), 1.82–1.90 (m, 3H), 2.06–2.16 (m, 1H), 2.10 (s, 3H), 2.19 (q, J = 9.0, 1H), 2.26–2.37 (m, 2H), 2.84 (dd, J = 10.7, 10.7, 1H), 3.12 (dd, J = 10.7, 4.3, 1H), 3.18 (dt, J = 9.4, 1.7, 1H), 4.45–4.53 (m, 1H), 5.25–5.28 (m, 1H), 7.71 (dd, J = 5.6, 3.0, 2H), 7.82 (dd, J = 5.6, 3.0, 2H); MS (CI) 329 (M + 1), 269 (M - 59). Anal. Calcd for $\text{C}_{18}\text{H}_{20}\text{N}_2\text{O}_4$: C, 65.84; H, 6.14; N, 8.53. Found: C, 66.04; H, 6.43; N, 8.04. **21b**: $[\alpha]_D^{25} - 32^\circ$ (c = 0.6, CHCl_3); IR (NaCl) 2940, 1740, 1710; $^1\text{H NMR}$ δ 1.59–1.65 (m, 1H), 1.71–1.83 (m, 2H), 1.96–2.16 (m, 3H), 2.04 (s, 3H), 2.67 (dt, J = 10.6, 6.4, 1H), 2.99–3.06 (m, 1H), 3.12 (dt, J = 9.8, 2.6, 1H), 3.63 (dd, 13.7, 7.3, J = 13.7, 7.3, 1H), 3.73–3.78 (m, 2H), 5.08–5.11 (m, 1H), 7.72 (dd, J = 5.5, 3.0, 2H), 7.85 (dd, J = 5.5, 3.0, 2H); MS (CI) 329 (M + 1), 168 (M - 160, CH_2Nphth). Anal. Calcd for $\text{C}_{18}\text{H}_{20}\text{N}_2\text{O}_4$: C, 65.84; H, 6.14; N, 8.53. Found: C, 66.19; H, 6.34; N, 7.98.

(1S,6R,8aS)-6-Acetamido-1,2,3,5,6,7,8,8a-octahydroindoliziny Acetate (20c). **A.** Compound **20b** (5 mg, 0.015 mmol) and hydrazine hydrate (22 μL , 0.45 mmol) in EtOH (3 mL) were

refluxed for 4 h. After evaporation of the solvent, pyridine (0.3 mL) and acetic acid anhydride (0.3 mL) were added and the mixture was stirred for another 4 h. Then, the solvents were evaporated, and the residue was filtered on a short silica gel column (CHCl₃:MeOH 95:5) to give **20c** (2 mg, 55%).

B: A mixture of **20a** (30 mg, 0.134 mmol) and Pd/C (10% 10 mg) in MeOH (3 mL) was stirred for 16 h under a balloon of hydrogen at rt. The reaction mixture was filtered, and the solvent was evaporated. After addition of pyridine (0.5 mL), and acetic acid anhydride (0.5 mL) it was stirred for 4 h. Then the mixture was evaporated, and the residue was filtered on a short silica gel column (CHCl₃:MeOH, 95:5) to give **20c** (14 mg, 43%) as colorless crystals: mp 203 °C; [α]_D²³ +12.4° (*c* = 0.75, CHCl₃), for *ent*-**20c**; lit.³ [α]_D²³ -12° (*c* = 0.7, CHCl₃). Spectroscopic data are identical with those reported for *ent*-**20c** (lit.³).

(1S,5S,7aS)-5-(Acetamidomethyl)-2,3,5,6,7,7a-hexahydropyrroliziny Acetate (21c). A solution of **21b** (16 mg, 0.05 mmol) and hydrazine hydrate (88 μ L, 1.8 mmol) in EtOH (3 mL) was refluxed for 4 h. The solvent was then removed, and the residue was stirred with pyridine (0.5 mL) and acetic acid anhydride (0.5 mL) for another 4 h. After evaporation, the residue was filtered on a short silica gel column (CHCl₃:MeOH 95:5) to give **21c** (8 mg, 69%) as a colorless oil: [α]_D²³ -40° (*c* = 0.8, CHCl₃); IR (NaCl) (cm⁻¹) 3280, 1740, 1660; ¹H NMR δ 1.63–1.72 (m, 1H), 1.74–1.79 (m, 2H), 1.96–2.09 (m, 2H), 2.05 (s, 3H), 2.07 (s, 3H), 2.11–2.15 (m, 1H), 2.65–2.71 (dt, *J* = 10.3, 6.4, 1H), 2.89–2.95 (m, 1H), 3.13–3.17 (m, 1H), 3.19–3.25 (m, 1H), 3.28–3.35 (m, 1H), 3.71–3.76 (m, 1H), 5.13–5.16 (m, 1H), 6.19 (bs, 1H, NH); MS (CI) 241 (M + 1), 181 (M - 59), 168 (M - 72, CH₂Ac). Anal. C₁₂H₂₀N₂O₃: C, 59.98; H, 8.39; N, 11.66. Found: C, 59.10; H, 8.81; N, 10.96.

(1S,6R,8aS)-6-Amino-1,2,3,5,6,7,8,8a-octahydroindoliziny Acetate (ent-3b). A mixture of **20a** (5 mg, 0.02 mmol) and Pd/C in MeOH was stirred for 16 h at rt under a balloon of hydrogen. The reaction mixture was filtered, and the solvent was evaporated to give *ent*-**3b** (3 mg, 68%) as a colorless oil. Spectroscopic data are identical to those reported for **3b** and *ent*-**3b** (lit.^{3,5j,m}).

(1S,8aS)-6-(Hydroxyimino)-1,2,3,5,6,7,8,8a-octahydroindoliziny Acetate (22). To a mixture of oxalyl chloride (5.0

μ L, 0.006 mmol) in CH₂Cl₂ (0.5 mL) were added at -60 °C DMSO (9.0 μ L, 0.012 mmol) dissolved in CH₂Cl₂ (0.05 mL) and subsequently, **19** (12 mg, 0.006 mmol), also dissolved in CH₂Cl₂ (0.05 mL). The mixture was stirred for 15 min, when Et₃N (40 μ L, 0.03 mmol) was added. After 5 min, a saturated NaHCO₃ solution was added. After extraction with CH₂Cl₂, the organic layer was dried (MgSO₄) and evaporated. The residue was heated in a mixture of EtOH (2 mL), pyridine (1 mL), and H₂-NOH·HCl (15 mg, 0.22 mmol) for 4 h at 80 °C. After a further 16 h at rt, the mixture was concentrated and CH₂Cl₂ and saturated NaHCO₃ were added. The organic layer was separated, dried (MgSO₄), and evaporated, and the residue was purified by flash chromatography (CH₂Cl₂:MeOH, 95:5) to give **22** (12 mg, 81%, 3:1 mixture of syn/anti isomers) as a colorless oil. Spectroscopic data (IR, ¹H NMR) are identical to those reported for racemic **22** (lit.^{5b}).

(1S,6S,8aS)-6-Acetamido-1,2,3,5,6,7,8,8a-octahydroindoliziny Acetate (23). According to ref 5b, a mixture of **22** (10 mg, 0.047 mmol) and PtO₂ in EtOH (3.5 mL) and concentrated HCl (0.2 mL) was stirred for 16 h at rt under a balloon of hydrogen. The reaction mixture was filtered, and the solvent was evaporated. Then, pyridine (1.5 mL) and Ac₂O (1 mL) were added to the residue. After being stirred for 3 h at rt, the mixture was concentrated and the residue was purified by flash chromatography (CH₂Cl₂: MeOH, 97:3) to give **23** (2 mg, 20%) as a colorless solid: mp 130–135 °C (ref 5j, 139–141 °C); ¹H NMR δ 1.41–1.48 (m, 1H), 1.48–1.57 (m, 1H), 1.73–1.82 (m, 1H), 1.87–1.93 (m, 1H), 1.95–1.98 (m, 1H), 2.01 (s, 3H), 2.02–2.11 (m, 2H), 2.09 (s, 3H), 2.18 (dd, *J* = 11.1, 2.5, 1H), 2.25–2.33 (m, 1H), 3.03 (d, *J* = 11.5, 1H), 3.09 (td, *J* = 9.4, 1.7, 1H), 4.18 (dt, *J* = 8.1, 2.6, 1H), 5.25 (ddd, *J* = 7.7, 5.1, 2.5, 1H), 6.31 (d, *J* = 6.4, NH); MS (CI) 241 (M + 1).

Acknowledgment. This work is supported by the Deutsche Forschungsgemeinschaft and the Fonds der Chemischen Industrie. Thanks are also due to Prof. Dr. K. T. Wanner (University of Munich) for supplying D.J. with a fellowship.

JO950144+